Kairos Pharma, Ltd. (KAPA) Income Statement
KAPA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsKAPA revenue and net income
KAPA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
KAPA quarterly EPS vs estimates
Kairos Pharma beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 13, 2026 (estimate $-0.63).
KAPA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $160,000 | $160,000 | $160,000 | $98,000 | — |
| Gross profit | — | −$160,000 | −$160,000 | −$160,000 | −$98,000 | — |
| Research & development | $2.1M | $414,000 | $82,000 | $87,000 | $183,000 | $20,000 |
| Sales, general & admin | $3.4M | $1.9M | $1.5M | $324,000 | $1.7M | $1.0M |
| Total operating expenses | $5.6M | $2.2M | $1.6M | $411,000 | $1.8M | $1.0M |
| Operating income | −$5.6M | −$2.3M | −$1.7M | −$571,000 | −$1.9M | −$1.0M |
| Interest income | $125,000 | $0 | — | — | — | — |
| Interest expense | $0 | $859,000 | $98,000 | $479,000 | $202,000 | $5,411 |
| Income before taxes | −$5.4M | −$2.6M | −$1.8M | −$1.1M | −$2.1M | −$1.1M |
| Income taxes | — | −$2.6M | — | — | — | — |
| Net income | −$5.4M | −$2.6M | −$1.8M | −$1.1M | −$2.1M | −$1.1M |
| EBITDA | −$5.3M | −$1.6M | −$1.6M | −$411,000 | −$1.8M | −$1.0M |
| EPS (diluted) | −$0.25 | −$0.17 | −$1.21 | −$0.71 | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $40,000 | −$120,000 | $40,000 | $40,000 | $40,000 | — | $40,000 | $40,000 | $40,000 | $40,000 | $40,000 |
| Gross profit | — | −$40,000 | $120,000 | −$40,000 | −$40,000 | −$40,000 | — | −$40,000 | −$40,000 | −$40,000 | −$40,000 | −$40,000 |
| Research & development | $619,000 | $684,000 | $538,000 | $608,000 | $496,000 | $493,000 | $172,000 | $14,000 | $63,000 | $165,000 | $7,000 | $33,000 |
| Sales, general & admin | $798,000 | $1.0M | $837,000 | $787,000 | $920,000 | $733,000 | $1.2M | $329,000 | $119,000 | $82,000 | $1.0M | $214,000 |
| Total operating expenses | $1.4M | $1.6M | $1.7M | $1.4M | $1.5M | $1.3M | $1.4M | $343,000 | $182,000 | $247,000 | $1.0M | $247,000 |
| Operating income | −$1.4M | −$1.6M | −$1.6M | −$1.4M | −$1.5M | −$1.3M | −$1.4M | −$383,000 | −$222,000 | −$287,000 | −$1.1M | −$287,000 |
| Interest income | $29,000 | $36,000 | $50,000 | $37,000 | $34,000 | $4,000 | — | $0 | $0 | $0 | — | — |
| Interest expense | — | — | $0 | $0 | $0 | $133,000 | $0 | $664,000 | $31,000 | $36,000 | $29,000 | $25,000 |
| Income before taxes | −$1.4M | −$1.7M | −$1.4M | −$1.4M | −$1.4M | −$1.3M | −$980,000 | −$1.0M | −$253,000 | −$323,000 | −$1.1M | −$312,000 |
| Income taxes | — | — | — | — | — | −$2.6M | — | — | — | — | — | — |
| Net income | −$1.4M | −$1.7M | −$1.4M | −$1.4M | −$1.4M | −$1.3M | −$980,000 | −$1.0M | −$253,000 | −$323,000 | −$1.1M | −$312,000 |
| EBITDA | −$1.4M | −$1.6M | −$1.3M | −$1.4M | −$1.4M | −$1.2M | — | −$342,999 | −$182,000 | −$247,000 | −$1.0M | −$247,000 |
| EPS (diluted) | −$0.06 | −$0.08 | −$0.07 | −$0.07 | −$0.08 | −$0.03 | −$0.05 | −$0.10 | −$0.02 | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in KAPA's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
KAPA financial results
Kairos Pharma reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $5.4 million. Diluted earnings per share came to −$0.25.
See the KAPA stock overview for the latest quote and news, or the KAPA chart for price history and technical indicators.
KAPA income statement FAQ
Does Kairos Pharma have revenue?
Kairos Pharma reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Kairos Pharma profitable?
No. Kairos Pharma reported a net loss of $5.4 million in fiscal 2025.
How much does Kairos Pharma spend on research and development?
Kairos Pharma spent $2.1 million on research and development in fiscal 2025.
What are Kairos Pharma's earnings per share?
Kairos Pharma earned $-0.25 per diluted share in fiscal 2025, compared with $-0.17 a year earlier.
When will Kairos Pharma report its next earnings?
Kairos Pharma is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Kairos Pharma's fiscal year end?
Kairos Pharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.